These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 9859685)
1. [Long-term complications of treatment with levodopa]. Castro García A; Sesar Ignacio A Neurologia; 1998; 13 Suppl 1():41-8. PubMed ID: 9859685 [No Abstract] [Full Text] [Related]
2. Ropinirole as compared with levodopa in Parkinson's disease. Weiner WJ; Factor SA N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001687 [No Abstract] [Full Text] [Related]
3. Current controversies: levodopa in the treatment of Parkinson's disease. Sharma JC; Vassallo M; Ross IN Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129 [No Abstract] [Full Text] [Related]
4. Ropinirole as compared with levodopa in Parkinson's disease. Frucht S N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001686 [No Abstract] [Full Text] [Related]
5. Ropinirole as compared with levodopa in Parkinson's disease. Yamamoto T N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001685 [No Abstract] [Full Text] [Related]
6. Levodopa in the treatment of Parkinson's disease: current controversies. Gerlach M; Reichmann H; Riederer P Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130 [No Abstract] [Full Text] [Related]
7. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Stacy M; Galbreath A Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491 [TBL] [Abstract][Full Text] [Related]
8. [Physiopathology of the dyskinesias induced by L-dopa]. Grandas F; López-Ariztegui N Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682 [TBL] [Abstract][Full Text] [Related]
9. Levodopa in the early treatment of Parkinson's disease. Murata M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036 [TBL] [Abstract][Full Text] [Related]
12. Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance. Ghiglieri V; Picconi B; Calabresi P Mov Disord; 2010 Aug; 25(11):1527-9. PubMed ID: 20623774 [No Abstract] [Full Text] [Related]
13. Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease. Prashantha DK; Pal PK Parkinsonism Relat Disord; 2009 Nov; 15(9):718-9. PubMed ID: 19157953 [No Abstract] [Full Text] [Related]
14. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399 [No Abstract] [Full Text] [Related]
17. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Peppe A; Dambrosia JM; Chase TN Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213 [No Abstract] [Full Text] [Related]
18. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756 [TBL] [Abstract][Full Text] [Related]
19. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]. Wedekind S MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622 [No Abstract] [Full Text] [Related]
20. What to do when Sinemet fails: Part one. Klawans HL Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692 [No Abstract] [Full Text] [Related] [Next] [New Search]